Onkure Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Onkure Therapeutics, Inc. (OKUR) on August 12, 2026, reporting events occurring on August 7, 2026. The Company is a Delaware corporation headquartered in Boulder, Colorado, and is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a corporate action regarding equity compensation.
Material Changes
The primary material event is the Board-approved repricing of underwater stock options on August 7, 2026.
- Scope: Approximately 1.7 million shares underlying options granted prior to January 1, 2025, with original exercise prices of $10.00 or higher.
- New Exercise Price: Reduced to $4.14 per share (the closing stock price on the Effective Date).
- Original Prices: Ranged from $13.99 to $24.59 per share.
- Executive Impact:
- Nicholas A. Saccomano (CEO): 571,423 shares repriced (original prices $13.99–$21.20).
- Samuel Agresta (CMO): 149,984 shares repriced (original prices $13.99–$18.20).
- Jason Leverone (CFO): 141,714 shares repriced (original prices $13.99–$21.20).
- Retention Requirement: To exercise at the new price, holders must remain employed for 18 months (senior management) or 12 months (other employees). Failure to meet this requirement triggers a premium exercise price equal to the original price.
Guidance, Outlook, and Management Commentary
Management stated the repricing was designed to provide retention and performance incentives without incurring significant stock dilution from new grants or cash expenditures. The Board considered various alternatives and consulted with a compensation consultant before approval. No specific financial guidance or outlook for future periods is provided in this filing.
Investor Verification Checklist
- Verify the total number of shares underlying the repriced options (approx. 1.7 million) against the Company's total outstanding share count to assess dilution impact.
- Confirm the current stock price relative to the new exercise price of $4.14 to evaluate immediate intrinsic value.
- Review the specific vesting schedules and expiration dates of the affected options, as these terms were not altered.
- Monitor future filings for any changes in executive compensation or equity plan amendments resulting from this action.